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Background:Muscarinic receptors can form both homo- and hetero-oligomers.
Results:Co-expression of M2 andM3 receptors resulted in concurrent detection of both homomer and heteromer interactions
and regulation of M2-containing forms by agonist.
Conclusion: Co-existing receptor oligomers display differential regulation.
Significance:Oligomers of closely related receptors display distinct properties that may be targeted therapeutically.
Each subtype of the muscarinic receptor family of G protein-
coupled receptors is activated by similar concentrations of the
neurotransmitter acetylcholine or closely related synthetic ana-
logs such as carbachol. However, pharmacological selectivity
can be generated by the introduction of a pair of mutations to
produceReceptorActivated Solely by Synthetic Ligand (RASSL)
forms of muscarinic receptors. These display loss of potency for
acetylcholine/carbachol alongside a concurrent gain in potency
for the ligand clozapine N-oxide. Co-expression of a form of
wild type human M2 and a RASSL variant of the human M3
receptor resulted in concurrent detection of each ofM2-M2 and
M3-M3 homomers alongside M2-M3 heteromers at the surface
of stably transfected Flp-InTMT-RExTM 293 cells. In this setting
occupancy of the receptors with a muscarinic antagonist was
without detectable effect on any of the muscarinic oligomers.
However, selective agonist occupancy of the M2 receptor
resulted in enhanced M2-M2 homomer interactions but de-
creased M2-M3 heteromer interactions. By contrast, selective
activation of the M3 RASSL receptor did not significantly alter
either M3-M3 homomer or M2-M3 heteromer interactions.
Selectively targeting closely related receptor oligomers may
provide novel therapeutic opportunities.
Members of the family of muscarinic acetylcholine recep-
tors constitute models for understanding more broadly the
superfamily of rhodopsin-like G protein-coupled receptors
(GPCRs)3 in terms of signaling, structure and pharmacology
(1–3). The existence of complexes between muscarinic recep-
tors, in the form of homomers and heteromers has been
reported previously (4–9) and the basis and importance of di-
merization/oligomerization involvingmembers of this group of
GPCRs has been discussed extensively (10–12).
The growing availability of crystal structures of different rho-
dopsin-like GPCRs has, in many cases, shown potential inter-
action interfaces between monomeric units (13–15). However,
it remains uncertain if these are of physiological significance or
simply reflect the most effective way of producing a crystal lat-
tice.Moreover, it is clear that purified and reconstitutedmono-
meric units of such receptors are able to interact with hetero-
trimeric G proteins in a manner that is regulated by guanine
nucleotides and, therefore, in a functionally relevant manner
(16–17). In addition to this, there are widely conflicting views
on the stability of GPCR-GPCR interactions (18–21), whether
this varies substantially within closely related groups of GPCRs,
and on the effects or otherwise of receptor ligands on such
interactions (see Ref. 11 for review). Furthermore, although it is
widely accepted that co-expression of pairs of GPCRs that are
able to interactmay result in the concurrent presence of each of
heteromers containing both GPCRs as well as the correspond-
ing homomers, this has been challenging to demonstrate
directly (22). Herein, we use co-expression of forms of the
humanmuscarinicM2 andM3 receptors to explore these issues.
We demonstrate concurrent detection of M2-M2, M3-M3, and
M2-M3 interactions at the surface of cells and distinct agonist
regulation of these interactions.
Experimental Procedures
Materials—Materials for cell culture were from Sigma
Aldrich or Life Technologies unless otherwise stated. Cloza-
pine N-oxide (CNO) was from Enzo Life Sciences. Carbachol
and atropine were from Sigma-Aldrich. Immunological re-
agents able to identify the epitope tags were obtained fromNew
England Biolabs (anti-SNAP) or Roche (anti-HA). The antise-
rum directed against VSV epitope was produced in-house. All
secondary IgG, horseradish peroxidase-linked antibodies were
from GE Healthcare. The radioligand [3H]quinuclidinylben-
zilate ([3H]QNB) was from PerkinElmer. Flp-InTM T-RExTM
293 cells were from Life Technologies.
Molecular Constructs—Generation of the human (h)M3RASSL
mutant was described by Ref. 4. HA-CLIP-hM3RASSL and
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VSV-SNAP-hM2WT cDNA constructs were produced by
introducing the metabotropic glutamate 5 receptor (mGluR5)
signal sequence followed by either the VSV and SNAP tags or
the hemaglutinin (HA) andCLIP tags into theN terminus of the
hM2WT or hM3RASSL receptor, respectively (4, 23).
Generation of Flp-InTM T-RExTM 293 Cells Stably Expressing
Muscarinic Receptor Constructs—Cells were maintained in
complete Dulbecco’s modification of Eagle’s medium (DMEM)
without sodium pyruvate, 4500 mgl1 glucose, and L-gluta-
mine, supplementedwith 10% (v/v) fetal bovine serum, 1% (v/v)
penicillin/streptomycin mixture, 200 gml1 hygromycin B,
and 10 gml1 blasticidin in a humidified atmosphere. Single
stable Flp-InTM T-RExTM 293 cell lines able to inducibly
express the different cDNA constructs were generated as
described previously (4, 22–23). To constitutively co-express a
second receptor construct in these cells they were transfected
with the appropriate cDNA construct, as described above,
and antibiotic-resistant clones selected using 1 mgml1
G418. All such cell lines were initially screened by fluores-
cence microscopy for receptor expression based on covalent
binding of SNAP- or CLIP-tagged fluorophores and subse-
quently bymeasuring specific binding of [3H]QNB in cellmem-
brane preparations.
Cell Membrane Preparations—Cells treated or not with
doxycycline, were harvested after 24 h, in ice-cold phosphate-
buffered saline (PBS) and pellets were frozen at 80 °C for a
minimum of 1 h. Pellets were thawed and resuspended in ice-
cold 10 mM Tris, 0.1 mM EDTA, pH 7.4 (TE) buffer, supple-
mented with CompleteTM protease inhibitor mixture (Roche
Diagnostics). Cells were passed through a 25-gauge needle
(5–10 times) and then homogenized on ice, by 50 strokes in a
glass-on-teflon homogenizer. Homogenized cells were centri-
fuged at 200 g for 5min at 4 °C. The supernatant fraction was
removed and transferred to microcentrifuge tubes and sub-
jected to further centrifugation at 90,000 g for 45min at 4 °C.
The pellets were resuspended inTE buffer, and protein concen-
tration was assessed. Membrane preparations were either used
directly or kept at80 °C until required.
Radioligand Binding Studies—Binding using various concen-
trations of [3H]QNB was carried out using 5 g of membrane
protein per reaction in assay buffer (20 mM HEPES, 100 mM
NaCl, 10 mM MgCl2, pH 7.4). Nonspecific binding was defined
in the presence of 10M atropine. Reactionswere incubated for
2 h at 30 °C. Bound ligand was separated from free by vacuum
filtration through GF/C filters (Brandel Inc.). The filters were
washed twice with assay buffer, and bound ligand was esti-
mated by liquid scintillation spectrometry.
Cell Lysate Preparation and Immunoblotting—Cells were
harvested, washed twice in ice cold PBS, and pelleted by cen-
trifugation. The pellets were resuspended in radio-immuno-
precipitation buffer (50 mM HEPES, 150 mM NaCl, 1% Triton
X-100, 0.5% sodium deoxycholate, 10mMNaF, 5mM EDTA, 10
mM NaH2PO4, 5% ethylene glycol, pH 7.4), supplemented with
CompleteTM protease inhibitors mixture. Resuspended cells
were then placed on a rotating wheel for 30 min at 4 °C, and
subsequently centrifuged at 21,000  g, for 15 min at 4 °C.
Supernatants were collected, and the protein concentration of
the lysates determined. Sampleswere heated at 60–65 °C in 1
Laemmli buffer (10% w/v SDS, 10 mM dithiothreitol, 20% v/v
glycerol, 0.2 M Tris-HCl, 0.05% w/v bromphenol blue, pH 6.8).
The required amount of protein lysate was then loaded on
4–12% NuPAGETM Novex Bis-Tris gels (Life Technologies).
Following electrophoresis, proteins were transferred onto a
nitrocellulosemembrane, blocked, and subsequently incubated
with the primary antibody/antiserum in 5% fat-free milk TBST
(2 mM Tris-base, 15 mM NaCl, and 0.1% v/v Tween 20, pH 7.4)
at 4 °C, overnight. After 5  5 min washing steps with TBST,
the appropriate horseradish peroxidase-conjugated IgG sec-
ondary antibody was incubated with the membrane at room
temperature for 1 h. Immunoblots were developed using en-
hanced chemiluminescence solution (Pierce).
Epifluorescence Imaging of LivingCells—Cellswere seeded on
poly-D-lysine pre-coated cover slips (0.0 mm thickness) to
500,000 cells per cover slip and incubated overnight in the pres-
ence or absence of doxycycline in complete DMEM. Cells that
expressed HA-CLIP-hM3RASSL receptor were labeled with 5
M CLIP-Surface 488 while those expressing VSV-SNAP-
hM2WTwere labeled using 5MSNAP-Surface 549 (NewEng-
landBiolabs) in completeDMEMfor 30min at 37 °C in 5%CO2.
Cells were washed three times with complete DMEM and once
with HEPES physiological saline solution (130 mM NaCl, 5 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, pH 7.4, and 10
mM D-glucose). Cover slips were imaged using an inverted
Nikon TE2000-E microscope (Nikon Instruments, Melville,
NY) equipped with a 40 (numerical aperture-1.3) oil-immer-
sion Pan Fluor lens and a cooled digital Photometrics Cool
Snap-HQ charge-coupled device camera (Roper Scientific,
Trenton, NJ).
Homogeneous Time-resolved FRET (htrFRET)—Cells were
grown to 100,000 per well on poly-D-lysine pre-treated 96-well
solid black bottom plates (Greiner Bio-One). Cells were
inducedwith doxycycline at the stated concentration for 24 h to
express the receptor(s) of interest. After 24 h induction, cell
surface receptor expression was monitored by adding 10 nM
SNAP-Lumi4Tb or 20 nM CLIP-Lumi4Tb. After incubation
at 37 °C/5% CO2 for 1 h, cells were washed three times with
labeling medium (Cisbio Bioassays), and the fluorescence
output was read at 620 nm using a PheraStar FS (BMG Lab
technologies).
In htrFRET experiments various combinations of energy
donor:acceptor were used to detect either homomers or het-
eromers. Detection of hM2WT homomers was carried out by
labeling with 5 nM SNAP-Lumi4Tb with varying concentra-
tions of SNAP-Red. hM3RASSL homomers were detected by
labelingwith 10 nMCLIP-Lumi4Tb and varying concentrations
of CLIP-Red. Heteromeric interactions between hM2WT and
hM3RASSL were detected using 5 nM SNAP-Lumi4Tb with
varying concentrations of CLIP-Red, or the reverse combina-
tion, 10 nM CLIP-Lumi4Tb with varying concentrations of
SNAP-Red. Labeling reactions were carried out for 1 h at
37 °C/5% CO2. Cells were then washed three times with 100 l
per well labeling medium and plates were either read directly
after this or further processed to test the effect of receptor
ligands. For the latter experiments, ligands were added to the
plates after the washing step and subsequently incubated at the
noted temperature and times prior to measurements using a
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PheraStar FS. Both the emission signal from the SNAP-
Lumi4Tb or CLIP-Lumi4Tb (620 nm) and the FRET signal
emanating from the acceptor SNAP-Red orCLIP-Red (665 nm)
were recorded. Specific 620 nm fluorescence, 665 nm FRET or
665:620 ratio values are shown as the difference between signals
obtained from induced and un-induced cells.
Triple Labeling htrFRET—Cells were plated, grown, and
treated with doxycycline in the same way as described in the
previous section. The cells were then simultaneously labeled
with three different, but spectrally compatible htrFRET sub-
strates.One donorwas used at a time, either SNAP-Lumi4Tb (5
nM) or CLIP-Lumi4Tb (10 nM), in combination with SNAP-
Green (100 nM) and CLIP-Red (100 nM). The substrates were
prepared at 3 the final concentrations in labeling buffer and
25l of each was added per well. Cells were incubated for 1 h at
37 °C/5% CO2 and washed three times with labeling buffer.
Ligands were added to the plates and incubated at the set time
points after which the plates were read using a PheraStar FS.
Two different protocols were used to measure the fluorescence
output corresponding to energy transfer to the two acceptors,
CLIP-Red at 665 nm and SNAP-Green at 520 nm. The donor
emission at 620 nm originating from either SNAP-Lumi4Tb or
CLIP-Lumi4Tb was also measured in both protocols.
InositolMonophosphate Accumulation Assay—A suspension
of 10,000 cells per assay point was prepared in stimulation
buffer (10mMHEPES, 1mMCaCl2, 0.5 mMMgCl2, 4.2 mMKCl,
146 mM NaCl, 5.5 mM glucose, and 50 mM LiCl, pH 7.4) and
incubated with ligands for 1 h at 37 °C/5% CO2 in a white Pro-
xiplate-384 Plus (PerkinElmer). After stimulation, cells were
lysed in a mixture of detection reagents prepared in lysis buffer
according to the manufacturer’s instructions (IP-One Tb kit,
Cisbio Bioassays) and incubated for a further hour at room
temperature. htrFRETwas thenmeasured using a PheraStar FS
and changes in inositol monophosphate levels were calculated
as ratio of 665/620 nm signals.
cAMP InhibitionAssay—Asuspension of 4,000 cells per assay
point was prepared in Hank’s Balanced Salt Solution (HBSS).
Cellswere co-incubatedwith forskolin (5M) and ligands for 30
min in a white Proxiplate-384 Plus. This step was followed by
lysis of cells using a mixture of detection reagents prepared in
lysis buffer according to manufacturer’s instructions (cAMP
dynamic 2 kit, Cisbio Bioassays) and incubation for 1 h at room
temperature. htrFRETwasmeasured on a PheraStar FS and the
reduction of cAMP levels was calculated as ratio of 665/620 nm.
Results
To explore aspects of the potential oligomerization of the
wild type (WT) human (h) muscarinic M2 acetylcholine recep-
tor, a construct (VSV-SNAP-hM2WT) was generated in which
the extracellular N-terminal domain was modified to incorpo-
rate both the VSV peptide epitope tag and the SNAP protein
tag sequences. This was cloned into the doxycycline-induc-
ible locus of Flp-InTM T-RExTM 293 cells and a transfected
population selected. Doxycycline-regulated expression of this
construct was assessed in three distinct ways. Firstly, immuno-
blotting with an anti-SNAP/CLIP antiserum of SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) resolved lysates of cells
that had been maintained for 24 h in the presence of different
concentrations of doxycycline identified specific induction of
the receptor construct as a polypeptide with apparent molecu-
larmass in the region of 80 kDa (Fig. 1A). No equivalent species
was detected either in lysates of these cells grown in the absence
of doxycycline or in lysates of parental, non-transfected Flp-
InTM T-RExTM 293 cells (Fig. 1A). Secondly, doxycycline-in-
duced expression and effective cell surface delivery of the con-
struct was defined by fluorescence emission at 620 nm
following excitation at 337 nm, subsequent to adding the
SNAP-tag label SNAP-Lumi4Tb to intact cells. This reflects
covalent attachment of the label to the SNAP tag of the con-
struct. This is located in the extracellular milieu because the
N-terminal domain of cell surface targeted GPCRs is antici-
pated to be outside the cell (Fig. 1B). Third, specific binding of
concentrations of the muscarinic antagonist [3H]QNB, close to
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FIGURE 1. Inducible control of hM2WT receptor expression. VSV-SNAP-
hM2WTwas cloned into the Flp-In
TM TRExTM locus of Flp-InTM TRExTM 293 cells
and a population of stably transfected cells isolated. A, lysates of these cells,
maintained for 24 h in the absence (0 Dox) or presence of the indicated con-
centration of doxycycline, were prepared and resolved by SDS-PAGE. Lysate
of parental non-transfected Flp-InTM TRExTM 293 cells (Flp-In) provided a neg-
ative control. Immunoblotting with an anti-SNAP/CLIP antiserum identified
the receptor construct. B, intact Flp-InTM TRExTM 293 cells harboring VSV-
SNAP-hM2WT and treated for 24 h with the indicated concentration of doxy-
cycline were treated with SNAP-Lumi4Tb (5 nM). Following washing, fluores-
cence emission at 620 nm following excitation at 337 nmdefined the relative
expression levels of VSV-SNAP-hM2WT at the cell surface. C, membrane prep-
arations from cells as in Bwere used to define the specific binding of [3H]QNB
(0.16–0.45 nM in individual experiments). Data are means S.E., n 3.
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theKd as assessed in saturation binding studies (0.30 0.07 nM,
mean  S.E., n  4), to membranes of doxycycline-induced
VSV-SNAP-hM2WTcells generated a qualitatively similar pro-
file as labeling of the construct with SNAP-Lumi4Tb (Fig. 1C).
We have previously characterized VSV- and SNAP-tagged
forms of both the WT muscarinic hM3 acetylcholine receptor
and a chemically engineered, Receptor Activated Solely by Syn-
thetic Ligand (RASSL) variant (4, 23–24). This form is not able
to bind or respond effectively to acetylcholine or related syn-
thetic analogs. Rather, it is activated by the usually inert chem-
ical ligand clozapine N-oxide (CNO) (23–24). Now, a modifi-
cation of this construct to generate HA-CLIP-hM3RASSL in
which the N-terminal VSV- and SNAP-tags were replaced with
the HA peptide epitope tag and the CLIP protein tag sequence
was generated. This was also cloned into the doxycycline-in-
ducible locus of Flp-InTM T-RExTM 293 cells. Doxycycline-in-
duced expression and cell surface delivery of this construct was
also characterized by immunoblotting to detect each of the
CLIP- and HA-tags (Fig. 2A) and, now, by the binding of CLIP-
Lumi4Tb (Fig. 2B). As anticipated from the substantially larger
third intracellular loop of the hM3 receptor compared with
hM2, the apparent molecular mass of the predominant form of
HA-CLIP-hM3RASSL identified by the SNAP/CLIP antiserum
was in the region of 110 kDa (Fig. 2A). Such RASSL forms of
muscarinic receptors display modestly reduced affinity for
many antagonist ligands (24), including [3H]QNB, compared
with the equivalentWT receptor. Preliminary studies indicated
theKd of [3H]QNB forHA-CLIP-hM3RASSL to be in the region
of 2.5 nM. Therefore, by measuring the specific binding of a
substantially higher concentration of [3H]QNB (15 nM) than
used for VSV-SNAP-hM2WT it was also possible to quantify
expression of HA-CLIP-hM3RASSL (Fig. 2C). Noticeably,
although the anti-SNAP/CLIP antiserum identified two forms
of HA-CLIP-hM3RASSL, the HA antiserum identified only the
more rapidly migrating and less prominent form (Fig. 2A). Pre-
treatment of cells during the period of receptor induction with
the de novo N-glycosylation inhibitor tunicamycin demon-
strated the form with lower mobility, which was not identified
by the anti-HA antiserum, to be the mature N-glycosylated
form. Moreover, equivalent studies indicated that VSV-SNAP-
hM2WTwas alsoN-glycosylated in the absence of tunicamycin
treatment (Fig. 3) and that these mature forms of the receptors
were the predominant species present.
In cells induced to express VSV-SNAP-hM2WTaddition of a
single concentration of SNAP-Lumi4Tb, as potential energy
donor, along with varying concentrations of SNAP-Red, as
potential energy acceptor, generated bell-shapedhomogeneous
time-resolved (htr)FRET signals. These were detected as emis-
sion at 665 nm following excitation at 337 nm and are consis-
tent with VSV-SNAP-hM2WT existing, at least in part, as cell
surface homo-dimers/oligomers (Fig. 4A) (4). By contrast, no
such signals were produced in the absence of doxycycline-in-
duced receptor expression (Fig. 4A). To define that these
htrFRET signals reflected relevant homomeric protein-protein
interactions, and not simply proximity due to the level of recep-
tor expression causing crowding or bystander effects, we per-
formed equivalent experiments in Flp-InTM T-RExTM 293 cells
able to express the monomeric transmembrane protein CD86
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FIGURE 2. Characterization of hM3RASSL expression. HA-CLIP-hM3RASSL was cloned into the Flp-In
TM TRExTM locus of Flp-InTM TRExTM 293 cells and a
populationof stably transfected cells isolated.A, lysates of these cells,maintained for 24h in the absenceorpresenceof 10ngml1 doxycycline,wereprepared
and resolved by SDS-PAGE. These were then immunoblotted with either anti-SNAP/CLIP (left hand side) or anti-HA (right hand side). See “Results” for further
details.B, akin toFig. 1 intact Flp-InTMTRExTM293cells harboringHA-CLIP-hM3RASSLand treated for 24hwith the indicatedconcentrationsofdoxycyclinewere
treated with CLIP Lumi4Tb (10 nM). After washing, fluorescence emission at 620 nm following excitation at 337 nm defined the relative expression levels of
HA-CLIP-hM3RASSL at the cell surface. C, membrane preparations from cells as in Bwere used to define the specific binding of [
3H]QNB (14–20 nM in individual
experiments). Data are means S.E., n 3. Note: the substantially higher concentration of [3H]QNB used than in Fig. 1 reflects the loss in binding affinity of
antagonists associated with the RASSL version of hM3.
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(25) (Fig. 4A). This polypeptide was also modified to introduce
both the VSV- and SNAP-tag sequences into the extracellular
N-terminal domain. Here, addition of a combination of SNAP-
Lumi4Tb and varying concentrations of SNAP-Red did not
result in significant htrFRET signal in cells induced to express
VSV-SNAP-CD86. Indeed, the signal was indistinguishable
from cells in which expression of this construct was not in-
duced (Fig. 4A). These experiments were carefully designed to
result in cell surface expression of the same amount of VSV-
SNAP-CD86 as VSV-SNAP-hM2WT. This was measured
directly by the level of binding of SNAP-Lumi4Tb to each of the
receptors, as in Fig. 1B, as fluorescence at 620 nm following
excitation as 337 nm (Fig. 4B). Therefore, VSV-SNAP-hM2WT
is present within homo-oligomers at expression levels in which
such signals are not produced by a well characterized mono-
meric protein.
Addition of a single concentration of CLIP-Lumi4Tb, as
potential energy donor, along with varying concentrations of
CLIP-Red to cells induced to HA-CLIP-hM3RASSL also gener-
ated bell-shaped htrFRET signals (Fig. 4C). This was lacking in
cells not induced to express HA-CLIP-hM3RASSL (Fig. 4C).
These results also are consistent with homo-dimeric/oligomer-
ic HA-CLIP-hM3RASSL interactions (Fig. 4C), confirming pre-
vious reports of hM3-hM3 interactions (4).
To explore the potential for co-expressed hM2 and hM3 to
exist within heteromeric complexes, cells able to express VSV-
SNAP-hM2WT only following addition of doxycycline, were
further transfected with HA-CLIP-hM3RASSL and clones con-
stitutively expressing this receptor variant isolated. A substan-
tial number of cloneswere characterized in preliminary studies.
These identified examples in which the levels of constitutively
expressed HA-CLIP-hM3RASSL remained constant while
expression of varying levels of VSV-SNAP-hM2WT could be
achieved by cell maintenance in the presence of different
concentrations of doxycycline. A representative clone is
shown in Fig. 5. Cell surface VSV-SNAP-hM2WT and
HA-CLIP-hM3RASSL were imaged individually following
addition of the cell impermeant dyes SNAP-surface 549 or
CLIP-surface 488. As shown in Fig. 5A the CLIP-tagged recep-
tor was present both with and without doxycycline treatment
while the SNAP-tagged receptor was only present following
doxycycline treatment.Merging of these images indicated clear
co-localization of the two receptors at the resolution of light
microscopy (Fig. 5A). Levels of binding of CLIP-Lumi4Tb
(reflecting the presence of HA-CLIP-hM3RASSL) to these cells
were constant over a range of doxycycline concentrations. By
contrast, binding of SNAP-Lumi4Tb (reflecting the appearance
of VSV-SNAP-hM2WT) increased with increasing concentra-
tions of doxycycline (Fig. 5B). To better quantify the relative
levels of VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL
expressionwemeasured the specific binding of [3H]QNB. Con-
centrations (16–21.6 nM in individual experiments) were cal-
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FIGURE 4. Detection of hM2WT and hM3RASSL homo-oligomers in cells
induced to express either receptor individually. A and B, cells, as in Fig. 1,
able toexpressVSV-SNAP-hM2WT inadoxycycline-inducible fashion (squares
(A), dark bars (B)), were compared with equivalent cells able to express VSV-
SNAP-CD86uponadditionof doxycycline (circles (A), light bars (B)).A, htrFRET
wasmeasured following additionof SNAP-Lumi4Tb (10nM) and the indicated
range of concentrations of SNAP-Red in both uninduced cells (No Dox, open
symbols) and in cells induced to express the constructs by growth in the pres-
ence of the indicated concentrations of doxycycline (filled symbols). B, these
concentrations of doxycycline resulted in cell surface expression of the same
level of VSV-SNAP-hM2WT and VSV-SNAP-CD86 as detected by fluorescence
at 620 nm after excitation at 337 nm that reflects binding of added SNAP-
Lumi4Tb (10 nM). C, cells able to express HA-CLIP-hM3RASSL were uninduced
(NoDox, open symbols) or treated for 24 hwith the indicated concentration of
doxycycline to induce the receptor construct (filled symbols). These were
exposed to a combination of 20 nMCLIP Lumi4Tb and varying concentrations
of CLIP-Red. Following excitation at 337 nm, fluorescence emission at 665 nm
was assessed as a measure of htrFRET.
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culated to occupy some 87–90% of HA-CLIP-hM3RASSL and
more than 98% of VSV-SNAP-hM2WT in membranes pre-
pared from cells treated or not with doxycycline. This defined
that HA-CLIP-hM3RASSL was present at 1632 650 fmolmg
protein1. Moreover, because after treatment with 5 ngml1
doxycycline the combined level of expression of muscarinic
receptors was 4678  1481 fmolmg protein1 (Fig. 5C), these
studies indicated the hM2WT could be expressed at up to twice
the total level of hM3RASSL. In parallel sets of immunoblots of
SDS-PAGE-resolved samples, anti-VSV antibodies only de-
tected protein of the appropriate molecular mass, correspond-
ing to VSV-SNAP-hM2WT, following treatment of the cells
with doxycycline (Fig. 5D). Immunoblots using the combined
anti-SNAP/CLIP antiserum confirmed that a polypeptide(s) in
the region of 80 kDa (VSV-SNAP-hM2WT) was expressed in a
doxycycline-dependentmanner by these cells, while a polypep-
tide(s) in the region of 110 kDa (HA-CLIP-hM3RASSL) was
expressed constitutively (Fig. 5D).
Using these cells, without doxycycline treatment, homo-
meric HA-CLIP-hM3RASSL interactions were clearly detected
as htrFRET signal at 665 nm following addition of combina-
tions of CLIP-Lumi4Tb and CLIP-Red (Fig. 6A). Interestingly,
such interactions were maintained when the VSV-SNAP-
hM2WT construct was also expressed, i.e. following treatment
with doxycycline (Fig. 6A). By contrast, and as anticipated, no
htrFRET signal corresponding to VSV-SNAP-hM2WT ho-
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FIGURE 5. Characterization of cells able to co-express hM2WT and hM3RASSL. Cells, as in Fig. 1, able to express VSV-SNAP-hM2WT in a doxycycline-depen-
dent fashion were further transfected with HA-CLIP-hM3RASSL and clones expressing this receptor construct isolated. One specific clone is detailed. A, cells
were maintained in the absence or presence of 5 ngml1 doxycycline for 24 h and then either of the cell impermeable dyes, SNAP-surface 549 (to label cell
surface hM2WT) and CLIP-surface 488 (to label cell surface hM3RASSL), was added and the cells imaged. Where indicated the images corresponding to
SNAP-surface 549 andCLIP-surface 488 labelingweremerged.B, cellsweremaintained in the absenceor presenceof varying concentrations of doxycycline for
24h. Subsequently either SNAPLumi4Tb (openbars) orCLIP Lumi4Tb (filledbars)was addedand fluorescenceemissionat 620nmafter excitationat 337nmwas
measured to assess relative levels of cell surface VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL (n 6–8 for each doxycycline concentration). C, specific [
3H]QNB
binding tomembranes fromcellsmaintained in the absence or presence of 5 ngml1 doxycyclinewas assessed.Note: individual experimentswere performed
with 16–21.6 nM [3H]QNB to allow effective detection of hM3RASSL as well as hM2WT and resulted in poorer data quality due to the relatively poor specific to
nonspecific binding ratios at thesehigh concentrationsof [3H]QNB (meansS.E.,n4).D, immunoblotswereperformedonmembranesprepared fromeither
these cellsmaintained in the presence of the indicated concentrations of doxycycline for 24 h or fromparental Flp-InTM TRExTM 293 cells (Flp-In). Panels display
anti-VSV (hM2WT) (left hand panel) or anti-SNAP/CLIP (both hM2WT and hM3RASSL) (right hand panel) immunoreactivity.
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momers was detected in the absence of doxycycline, because
this receptor is absent.However, htrFRET signal corresponding
to VSV-SNAP-hM2WT homomers appeared at the cell surface
following doxycycline treatment of the cells (Fig. 6B). Impor-
tantly, in the doxycycline-induced cells addition of combina-
tions of SNAP-Lumi4Tb and CLIP-Red also demonstrated the
proximity of hM2WT and hM3RASSL, potentially within het-
eromeric oligomers (Fig. 6C). Moreover, hM2WT-hM3RASSL
hetero-interactions were also detected when the labeling pro-
tocol was reversed to use a combination of CLIP-Lumi4Tb and,
therefore, HA-CLIP-hM3RASSL as the energy donor, and
SNAP-Red and, therefore, VSV-G-SNAP hM2WT as energy
acceptor (Fig. 6C). Immunoprecipitation of VSV-SNAP-
hM2WT with anti-VSV antibodies resulted in co-immunopre-
cipitation of anti-HA immunoreactivity, corresponding to
HA-CLIP-hM3RASSL, only after doxycycline treatment had
resulted in the co-expression of the two receptors (Fig. 6D).
hM2 is linked predominantly to Pertussis toxin-sensitive, Gi-
family G proteins while hM3 is usually largely associated with
signaling via Gq/11-family G proteins. Moreover, although the
acetylcholine mimetic carbachol is able to activateWTmusca-
rinic receptors, it is reported to display very low potency at
RASSL forms of this receptor family (23, 24). This was con-
firmed in cells induced to express VSV-SNAP hM2WT in the
constitutive presence of HA-CLIP-hM3RASSL. Here carbachol
was able to effectively inhibit forskolin-stimulated cAMP pro-
duction with pEC50 6.9 0.1 (mean S.E., n 4). However,
in cells not induced to express VSV-SNAP-hM2WTand, there-
fore, with only HA-CLIP-hM3RASSL present, little inhibition
of forskolin-stimulated cAMP levels was noted at concentra-
tions of carbachol up to 1 M (Fig. 7A). By contrast, both in the
absence (pEC50 8.10 0.08) and presence (pEC50 8.00
0.18) (means S.E., n 5 in each case) of VSV-SNAPhM2WT,
CNO was able to potently stimulate the production of inositol
monophosphates (Fig. 7B). This is a downstream indicator of
Gq/G11 activation. Interestingly, although not reaching statisti-
cal significance, therewas a trend toward higher inositolmono-
phosphate production in response toCNOwhen the two recep-
tors were co-expressed (Fig. 7B). This did not reflect a direct
effect of CNO on the hM2WT receptor orthosteric binding
pocket because neither with nor without doxycycline induction
was carbachol able to cause a significant accumulation of ino-
sitol monophosphates in these cells (Fig. 7B). Importantly,
however, these studies did define the functionality of the
expressed constructs and confirmed the previously established
selectivity of the agonist ligands in this setting (23, 24).
Potential effects of ligands on the organization or stability
and regulation of GPCR oligomers is a complex topic in which
a range of observations have been reported (11). In cells
induced with doxycycline to allow co-expression of VSV-
SNAP-hM2WT andHA-CLIP-hM3RASSL, as noted above, co-
addition of a combination of SNAP-Lumi4Tb and CLIP-Red
resulted in detection of htrFRET signal, consistent with inter-
actions between the two receptors (Fig. 8A). Over a period of 40
min, exposure to a concentration (10 M) of the muscarinic
antagonist atropine that is sufficient to occupy fully both the
hM2WT and hM3RASSL constructs, had no greater effect on
the heteromer signal than addition of vehicle (Fig. 8A). By con-
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FIGURE 6. Detection of homomers of both hM2WT and hM3RASSL as well as hM2WT-hM3RASSL heteromers in cells expressing both muscarinic
receptor subtypes. Cells, as in Fig. 5, expressing HA-CLIP-hM3RASSL in a constitutive manner and able to express VSV-SNAP-hM2WT in a doxycycline-depen-
dent fashionwere employed.A, htrFRET studies using combinations of CLIP-Lumi4TbandCLIP-Reddemonstrate thepresenceof hM3RASSLhomomers inboth
the absence (filled symbols) and presence (open symbols) of hM2WT. B, htrFRET studies using combinations of SNAP-Lumi4Tb and SNAP-Red demonstrate the
presence of hM2WT homomers only after treatment with doxycycline (open symbols) and the expression of VSV-SNAP-hM2WT receptor. No such interactions
were detected without receptor induction (filled symbols). C, addition of combinations of either SNAP-Lumi4Tb and CLIP-Red (circles) or CLIP-Lumi4Tb and
SNAP-Red (squares) followedbyhtrFRET analysis shows also thepresenceof hM2WT-hM3RASSLheteromerswhen the two receptor subtypes are co-expressed.
D, lysates of untreated cells (Dox) or those treated with doxycycline () for various periods andmaintained in the presence of the N-glycosylation inhibitor
tunicamycin (Tun) were immunoprecipitated with anti-VSV. These samples were then resolved by SDS-PAGE and immunoblotted with anti-HA to detect
co-immunoprecipitation of HA-CLIP-hM3RASSL. As induction of expression of VSV-SNAP-hM2WT requires a significant period of time after addition of doxy-
cycline, co-immunoprecipitation is only observed at the later time points.Note:As shown in Fig. 1, anti-HA is only able to identify the non-N-glycosylated form
of HA-CLIP-hM3RASSL. This is why experiments were performed in tunicamycin-treated cells.
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trast, addition of either carbachol alone, or a combination of
carbachol and CNO, resulted in a substantial and rapid decline
in htrFRET signal corresponding to hM2WT-hM3RASSL inter-
actions (Fig. 8A). Unlike carbachol, CNO was unable to
produce such an effect when applied alone (Fig. 8A). When
equivalent studies were performed using a combination of
SNAP-Lumi4Tb and SNAP-Red to detect hM2 receptor
homomers, both carbachol alone and carbachol plus CNOnow
resulted instead in an extensive increase in htrFRET signal (Fig.
8B). Once again neither CNOalone, nor atropine had any effect
on the hM2 homomer htrFRET signal compared with vehicle-
treated cells (Fig. 8B). Unlike the hM2WT homomer, htrFRET
signal corresponding to the hM3RASSL homomer was not
affected in these cells in a ligand-dependent manner (Fig. 8C).
This was the case whether or not expression of VSV-SNAP-
hM2WT had been induced (Fig. 8C). Importantly, the effects of
carbachol on both the hM2WT homomer (pEC50 5.5 0.2)
and hM2WT-hM3RASSL heteromer (pEC50  5.2  0.3)
(means  S.E., n  4 in each case) interactions were concen-
tration-dependent (Fig. 9).
As an extension to these studies we attempted to identify
concurrently in the same cells both homo- and hetero-interac-
tions involving VSV-SNAP-hM2WT. SNAP- andCLIP-Lumi4Tb
have broad emission spectra. As such, upon excitation at 337 nm
they can potentially transfer energy to both Green (with
htrFRET output at 520 nm) and Red (with htrFRET output at
665 nm) energy acceptors. This potentially allows concurrent
dual color detection of multiple interactions of the energy
donor-tagged receptor.We, therefore, initially added amixture
of SNAP-Lumi4Tb and both CLIP-Red and SNAP-Green to
cells induced to co-express VSV-SNAP-hM2WT and
HA-CLIP-hM3RASSL. Such studies were indeed able to iden-
tify interactions of the energy donor-labeled hM2WTwith both
energy acceptor labeled hM2WT and hM3RASSL receptors
concurrently (Fig. 10, A and B). Moreover, as in the individual
htrFRET experiments reported above, concurrent analysis of
the two distinct interactions of the energy donor-labeled
hM2WT receptor showed an equivalent carbachol-mediated
decrease in hM2WT-hM3RASSLheteromeric interactions (Fig.
10A) and increase in hM2WT-hM2WT homomeric interac-
tions (Fig. 10B). Once again, themuscarinic antagonist atropine
was without effect (Fig. 10,A and B). Finally, in cells induced to
co-express the hM2WT and hM3RASSL receptors, labeling of
hM3RASSLwith the energy donor CLIP-Lumi4Tb and propor-
tions of both hM2WT and hM3RASSL respectively with SNAP-
Green and CLIP-Red, the hM2WT-hM3RASSL heteromeric
interactions were again specifically decreased by treatment
with carbachol (Fig. 10C). By contrast hM3RASSL homo-inter-
actions were once more unperturbed by addition of any of
CNO, carbachol, or atropine (Fig. 10D).
Discussion
Although it is well established that monomers of the individ-
ual subtypes of muscarinic acetylcholine receptors can exist in
proximity to one another (4, 26–28) and, indeed, have the
capacity to generate dimers and/or higher-order oligomers
(6–7, 9, 18, 27–28), a broad range of issues around such inter-
actions remain unresolved. Among these are the stability (19)
or otherwise (8, 18) of dimeric interactions, the overall dimen-
sions and organization of dimeric/oligomeric complexes (7, 9,
25) and the implications of this for the details of interaction
with heterotrimeric G proteins and downstream signal trans-
duction (11–12). Moreover, as muscarinic subtypes are
expressed at markedly different levels in different cells and tis-
sues this may, as suggested by some (25) but not other (19–20)
reports on both muscarinic and other rhodopsin-like family
GPCRs, affect the extent of their dimerization/oligomerization.
Furthermore, distinctmuscarinic receptor subtypesmay be co-
expressed in physiologically relevant cells (29–30). Although
the capacity for heteromeric interactions between variousmus-
carinic receptor pairs has been explored to some degree (26–
27), the propensity for this to occur concurrently with
homomerization, and its implications for function, have been
little explored to date. For example, M2 and M3 receptors are
co-expressed in smooth muscle but the functional importance
of this for the integration of signaling remains uncertain.
Within the current studies we have, therefore, addressed a
number of these issues by combinations of biochemical, bio-
physical, and chemical biology approaches.
Central to these studies was the use of cell surface hrtFRET,
based on the incorporation of SNAP- and CLIP-tags (31–32),
into various muscarinic receptor constructs. Such tagging
allowed the covalent incorporation of hrtFRET-competent
fluorophores into the extracellular N-terminal region of the
receptors via linkage to the engineered SNAP and CLIP protein
tags. Importantly, such large scalemodification of the N-termi-
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FIGURE7.hM2WTandhM3RASSLconstructsdisplay theanticipatedphar-
macological selectivity. Cells constitutively expressing HA-CLIP-hM3RASSL
and harboring VSV-SNAP-hM2WT at the doxycycline-inducible locus were
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ngml1 doxycycline for 24 h. Subsequently cells were employed tomeasure
the ability of carbachol (Cch) (circles) or CNO (squares) to produced inhibition
of forskolin-stimulated cAMP levels (A) or the capacity of either CNO or car-
bachol to mediate increases in levels of inositol monophosphates (B).
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nal domain of either the hM2 or hM3 receptor did not affect
their basic ligand pharmacology. Of equal importance was the
introduction of RASSL-inducing mutations into the hM3
receptor constructs (23–24). Particularly for the muscarinic
receptor family, such modified GPCRs are also frequently
denoted as DREADDs (Designer Receptors Exclusively Acti-
vated byDesignerDrugs) (33). The associated alteration in ago-
nist pharmacology so produced allowed for selective agonist
occupancy and activation of the hM2WT receptor (with the
acetylcholine mimetic carbachol) and the hM3RASSL receptor
(with the muscarinic RASSL agonist CNO) in cells co-express-
ing the two receptor subtypes. This was confirmed by demon-
strating both that carbachol-mediated inhibition of cAMP lev-
els was observed only following induced expression of the hM2
receptor and not when the hM3RASSL receptor was expressed
alone, and that CNO, but not carbachol, was able to promote
the production of inositol monophosphates via the hM3RASSL
receptor, both in the absence and presence of the hM2 WT
receptor. By contrast, the antagonist atropine was able to bind
to both receptors with similar affinity.
In cells able to express only either the SNAP-tagged hM2WT
receptor or the CLIP-tagged RASSL form of the hM3 receptor
htrFRET studies provided clear evidence for homomeric inter-
actions of each subtype. Although this was anticipated from
previous work, in cells constitutively expressing hM3RASSL
receptors, induced expression of the hM2WT receptor now
resulted in detection of hM2-hM2 interactions as well as hM2-
hM3 interactions at the surface of these cells without eliminat-
ing hM3-hM3 interactions. The most obvious interpretation of
these results is that receptor homomers can co-exist with rele-
vant heteromers perhaps, as suggested by Herrick-Davis et al.,
as stable and distinct dimers (20). However, it is important to
note that others have suggested such interactions to be more
dynamic (18, 34). Moreover, concurrent monitoring of hM2-
hM2 and hM2-hM3 interactions in dual color studies, in which
a single energy donor and two distinct energy acceptor reagents
were added concurrently, also provided evidence for each of
these interactions. This is the first time that such an approach
has been used to examine multiple interaction partners of a
GPCR simultaneously.
A common concern in studies on interactions involving cell
surface transmembrane proteins is that high level expression
may result in apparent interactions based on proximity that
reflect the levels of expression achieved. We addressed this in
two distinct ways. Firstly, for all the studies performed we gen-
erated and utilized stably transfected cell lines able to express
the receptor(s) of interest in a controlled, inducible manner.
Generally, studies that rely entirely on transient transfection
protocols encounter challenges due to high level expression of
the receptors, often incompletely processed, within subsets-
of the cell population. Herein, we demonstrated that the bulk of
each of the muscarinic receptor subtype constructs was appro-
priately N-glycosylated, as anticipated for mature, correctly
trafficked GPCRs. More importantly we also generated an
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equivalent cell line able to inducibly express VSV-SNAP-CD86.
CD86 is recognized as a monomeric single transmembrane
domain protein (25). Expression of this construct to the same
level as used to study VSV-SNAP-hM2WT generated no spe-
cific htrFRET signal upon addition of a combination of SNAP-
tag energy donor and acceptor species. This provided comfort
that the signals produced at these levels of expression of
VSV-SNAP-hM2WT did indeed reflect true receptor-receptor
interactions.
The further key outcome of these studies is that the agonist
carbachol was able to change energy transfer signals corre-
sponding to both hM2-hM2 andhM2-hM3 interactions. By con-
trast this ligand had no effects on hM3-hM3 interactions. This
latter feature was hardly surprising as the hM3RASSL con-
structs used in these studies were modified to have minimal
affinity for carbachol (23–24). However, in the case of the hM2-
hM2 and hM2-hM3 interactions the directionality of the effect
of carbachol was completely different. Both in cells expressing
only the hM2WTreceptor construct, and those expressing both
the hM2WTand the hM3RASSL receptors, carbachol increased
the htrFRET signal corresponding to hM2-hM2 homomers and
did so in both a time- and concentration-dependent manner.
Moreover, the EC50 for the ligand in producing these changes in
htrFRET was very similar to the affinity of carbachol at the
hM2WT receptor. This is consistent with the effects reflecting
receptor occupancy. By contrast carbachol decreased the
htrFRET signal corresponding to hM2WT-hM3RASSL interac-
tions. This was, however, once again both time- and concen-
tration-dependent. It could be argued in the hM2-hM3 co-ex-
pressing cells that the effect of carbachol was to diminish
hM2-hM3 interactions and that this then resulted in greater
hM2-hM2 interactions, i.e. to promote a heteromer to homomer
transition. However, although these effects of carbachol could
also be detected in triple labeling, ’dual color’ studies in which
the effects on the receptor complexes were measured con-
currently, further studies will be required to support such a
conclusion. Perhaps surprisingly, unlike carbachol, CNO was
unable to influence htrFRET signals corresponding to hM3-
-12 -10 -8 -6 -4 -2
0.0
0.2
0.4
0.6
0.8
1.0 0 min
40 min
log[carbachol] M
66
5/
62
0 
ra
ti
o
-12 -10 -8 -6 -4 -2
0.0
0.5
1.0
1.5
2.0
2.5 0 min
40 min
log[carbachol] M
66
5/
62
0 
ra
ti
o
A
hM2-hM3 HETEROMERS 
B hM2-hM2 HOMOMERS 
VSV-SNAP-hM2WT/HA-CLIP-hM3RASSL
FIGURE 9. Effects of carbachol onmuscarinic receptor quaternary organi-
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RASSL-hM3RASSL interactions to any greater extent than
addition of vehicle. This may reflect greater stability of hM3-
hM3 homomeric interactions compared with either hM2-hM2
homomers or hM2-hM3 heteromers. However, although iden-
tified as a highly selective activator of RASSL forms of musca-
rinic receptor subtypes, CNO is of course not a direct equiva-
lent of carbachol. This is despite CNO acting as an apparently
high efficacy agonist that, in awide range of assays, shows broad
similarity in capacity to activate and regulate the hM3RASSL as
either carbachol or acetylcholine do at thewild type hM3 recep-
tor (23). Although theremay be differences in details of efficacy
or bias of CNO at the hM3RASSL receptor in end points that
have not been assessed previously that may account for this
difference, a distinct explanation is that the hM2 and hM3
receptors differ in the basis or stability of their homomeric
interactions. It is notable in this regard that Calebiro et al. have
provided evidence for markedly different stability and propen-
sity of 1- and 2-adrenoceptors to form dimers and higher-
order oligomers (25), even though these receptors are highly
homologous and are activated by the same hormones.
This is not the first set of studies to suggest a capacity of
ligand to alter the organization and/or stability of a muscarinic
receptor homomer. Although muscarinic toxin 7, a highly
selective allosteric peptide ligand of theM1 subtype, binds (35–
36) in a very different manner to carbachol or CNO (23), it has
been reported to stabilize M1 receptor homomers (35–36). It
has also been suggested that the selective M1 receptor antago-
nist pirenzepine can promote dimerization of this receptor
(37).
Beyond possible differences in efficacy, one further observa-
tion that is difficult to provide a clear explanation for was the
marked difference in the effects of carbachol and CNO on
hM2WT-hM3RASSL interactions and, thus, on hM2-hM3 het-
eromers. Although difficult to demonstrate without making
further alterations in the ligand binding pocket to alter ligand
pharmacology, as has been done for the2-adrenoreceptor (38)
and the leukotriene B(4) receptor (39), which, to some extent
invalidates the basis of the experiment, it is anticipated that a
ligand effect across the interface of a receptor homo-dimer/
oligomer should be symmetric. Therefore, an effect of ligand
binding to one protomer is anticipated to be reciprocated by
(the same) agonist occupancy of the other protomer. Herein,
carbachol effects on hM2WT-hM3RASSL receptor interactions
were not recapitulated by CNO. This may simply reflect that
the hM2 and hM3 receptors are, of course, distinct species or
that the makeup of hM2WT-hM3RASSL receptor heteromers
is not simply 1:1 in oligomeric (7, 28) rather than dimeric con-
figurations. No-matter the basis for the lack of symmetry here,
this is topic that requires and deserves further consideration in
the future.
Notwithstanding this final point, the current studies offer a
broad range of novel insights into differences in ligand regula-
tion of hM2-hM2 versus hM3-hM3 interactions and provide a
one donor plus two acceptors strategy to concurrently assess
interactions of a protein with more than a single partner. The
molecular basis for the noted differences in ligand regulation
between closely related receptors will provide a drive for future
analysis.
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